1. Tolterodine ER reduced increased bladder wall thickness in women with overactive bladder. A randomized, placebo‐controlled, double‐blind, parallel group study
- Author
-
Simon Hill, Rhiannon Bray, Rufus Cartwright, Zhonghong Guan, Linda Cardozo, and Vik Khullar
- Subjects
Adult ,medicine.medical_specialty ,Adolescent ,Tolterodine Tartrate ,Urology ,media_common.quotation_subject ,Urinary Bladder ,030232 urology & nephrology ,Muscarinic Antagonists ,Placebo ,Urination ,law.invention ,Double blind ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Double-Blind Method ,Randomized controlled trial ,law ,Statistical significance ,Humans ,Medicine ,Aged ,Ultrasonography ,media_common ,030219 obstetrics & reproductive medicine ,Urinary Bladder, Overactive ,business.industry ,Age Factors ,Middle Aged ,Placebo Effect ,medicine.disease ,Treatment Outcome ,Urinary Incontinence ,Overactive bladder ,Delayed-Action Preparations ,Female ,Neurology (clinical) ,Tolterodine ,business ,Wall thickness ,medicine.drug - Abstract
AIMS We evaluated the effect of Tolterodine extended release (TER) versus placebo on bladder wall thickness (BWT) using transvaginal ultrasound in women with overactive bladder (OAB). MATERIALS AND METHODS We recruited 79 women with symptoms of OAB with a mean age of 47 years who had a BWT of at least 5 mm and a post-micturition volume of less than 50 mL at screening. Subjects received TER 4 mg or placebo once daily for the first 12 weeks of the study. For the subsequent 12 weeks, all subjects received TER 4 mg once daily. BWT was measured at screening, weeks 12 and 24. Subjects recorded number of micturitions, incontinence episodes and urgency episodes, and volume voided per micturition at regular intervals during the study. RESULTS Treatment with TER for 12 weeks produced a statistically significant decrease from baseline in BWT (mean [SD] = 0.9 [1.4] mm; P
- Published
- 2017